ClinicalTrials.gg

Program

pentanedioic acid imidazolyl ethanamide

Also written as “Ingavirin”, “Ingavirin, capsules, 90 mg” and “Ingavirin®”.

Its studies are mostly in Influenza, Human · Common Cold · COVID-19 · Breast Neoplasms, led by 2 companies.

Furthest: phase 4, since Apr 26, 201710 company-led studies, 2 open or runningNext primary completion: Dec 31, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Valenta Pharm JSC92 open or runningphase 4since Apr 26, 2017Dec 22, 2015Dec 31, 2027phase 1 · NCT07645534
Myelo Therapeutics10 open or runningphase 2since Feb 23, 2016Feb 23, 2016none ahead

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Dec 22, 2015First study: phase 3 study in Common ColdNew to Valenta Pharm JSCValenta Pharm JSC · NCT02644018 · 190 enrolled · Russian Federation
  2. Feb 23, 2016Myelo Therapeutics’ first study: phase 2 study in Breast NeoplasmsNew to Myelo TherapeuticsMyelo Therapeutics · NCT02692742 · 137 enrolled · Germany
  3. Apr 26, 2017Phase 4 study in Common ColdValenta Pharm JSC · NCT03154515 · 445 enrolled · Russian Federation
  4. Jun 8, 20173 phase 3 studies in Influenza, HumanValenta Pharm JSC · NCT03189537, NCT03191097, NCT03206346
  5. Jan 28, 20222 phase 3 studiesValenta Pharm JSC · NCT05269290, NCT05216497
  6. Mar 11, 2024Phase 4 study in Influenza, HumanValenta Pharm JSC · NCT06315400 · 80 planned · Russian Federation
  7. May 12, 2026Phase 1 study in Influenza, HumanValenta Pharm JSC · NCT07645534 · 36 planned · Russia

Ahead

  1. Dec 31, 2027Primary completion: phase 1 study in Influenza, HumanValenta Pharm JSC · NCT07645534

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 10 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07645534Influenza, Human · Russia1RecruitingValenta Pharm JSCDec 31, 202736
NCT06315400Influenza, Human · Russian Federation4RecruitingValenta Pharm JSCDec 31, 202580
NCT05269290Influenza, Human · Russian Federation3CompletedValenta Pharm JSCApr 29, 2022240
NCT05216497COVID-19 · Russian Federation3CompletedValenta Pharm JSCJan 12, 2022233
NCT03206346Influenza, Human · Russian Federation3CompletedValenta Pharm JSCNov 2012161
NCT03191097Influenza, Human · Russian Federation3CompletedValenta Pharm JSCDec 2014310
NCT03189537Influenza, Human · Russian Federation3CompletedValenta Pharm JSCApr 19, 2011400
NCT03154515Common Cold · Russian Federation4CompletedValenta Pharm JSCApr 2014445
NCT02692742Breast Neoplasms · Germany2CompletedMyelo TherapeuticsNov 2017137
NCT02644018Common Cold · Russian Federation3CompletedValenta Pharm JSCMay 2016190

How it is read

Names in the registry

  • “Ingavirin”, 3 entries
  • “Ingavirin, capsules, 90 mg”, 1 entry
  • “Ingavirin®”, 1 entry
  • “Ingavirin®, syrup, 30 mg/5 ml”, 1 entry
  • “Ingavirin®, 90 mg capsules”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.